Harm Reduction Therapeutics

Harm Reduction Therapeutics In The News

The latest stories and news about Harm Reduction Therapeutics, OTC RiVive®, and naloxone

A2A Alliance Pharmaceuticals

A2A Alliance Pharmaceuticals and Harm Reduction Therapeutics Announce Strategic Partnership to Expand Access to Life-Saving OTC Naloxone 3mg Nasal Spray (RiVive™) to U.S. Federal Entities and Veterans

Aug 14, 2024

Statement Regarding High Dose Naloxone and Long Acting Nalmefene Opioid Overdose Reversal Formulations

Jul 29, 2024

Exploring Cost and the Emerging Landscape of Naloxone Competition

Jul 22, 2024

Drug Intervention Institute partners with Harm Reduction Therapeutics to provide low-cost life-saving RiVive™ 3 mg naloxone nasal spray inside ONEbox™

Mar 1, 2024

STAT

Higher naloxone doses have no impact on overdose survival, study shows

Feb 8, 2024

Bystander Naloxone Administration: Amounts and Dosages versus EMS Naloxone Administration

Feb 3, 2024

First Shipment of RiVive™ Brings Life-Saving Over-The-Counter Naloxone Nasal Spray One Step Closer to Those Who Need It Most

Dec 18, 2023

Open Society Supports an Innovative Model to Make Naloxone Easier to Access Amidst the U.S. Overdose Crisis

Dec 12, 2023

Narcan Now Available Over-the-counter – What to Know

Sep 5, 2023

Load More
Load More